Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.

Abstract

We conducted a single-blind trial of gamma-vinyl-GABA (GVG) in nine patients: seven with tardive dyskinesia, one with Meige syndrome, and one with Tourette syndrome. Five tardive dyskinesia patients completed the entire 11-week study and, as a group, demonstrated significant decreases in dyskinesia scores. Four of these five tardive dyskinesia patients showed clinically evident improvement, with approximately 30% reduction in dyskinetic symptoms. Other patients had no clinical benefit from GVG. Three patients had transient exacerbation of psychiatric symptoms after sudden withdrawal of GVG, and one patient experienced dose-related confusional episodes. Our results suggest that GABAergic drugs may have a role in treating patients with tardive dyskinesia.

• Authors: S M Stahl, J E Thornton, M L Simpson, P A Berger, M J Napoliello
• Journal: Biological psychiatry (Biol Psychiatry) Vol. 20 Issue 8 Pg. 888-93 (Aug 1985) ISSN: 0006-3223 [Print] United States
• PMID: 3861199 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Aminocaproates
• gamma-Aminobutyric Acid
• Vigabatrin

Topics

• Adult
• Aged
• Aminocaproates (adverse effects, therapeutic use)
• Confusion (chemically induced)
• Dyskinesia, Drug-Induced (drug therapy)
• Female
• Humans
• Male
• Meige Syndrome (drug therapy)
• Middle Aged
• Movement Disorders (drug therapy, physiopathology)
• Substance Withdrawal Syndrome
• Tourette Syndrome (drug therapy)
• Vigabatrin
• gamma-Aminobutyric Acid (physiology)